SCORAD Calculator – Atopic Dermatitis Severity Score

SCORAD stands for Scoring Atopic Dermatitis and is one of the most widely used tools for grading eczema severity. It combines three different dimensions of disease burden: the extent of skin involved, the visible intensity of key clinical signs, and the patient's own symptom experience. That structure makes it more informative than a simple rash description, because it captures both what the clinician sees and what the patient feels. The result is especially useful in dermatology follow-up, clinical trials, treatment comparisons, and documenting how severe a flare is at a specific point in time. The score is built from three components. Component A is extent, measured as the percent of body surface area affected from 0 to 100. Component B is the sum of six objective signs, each graded from 0 to 3: erythema, edema or papulation, oozing or crusts, excoriations, lichenification, and dryness. Component C adds the patient's symptom burden from pruritus and sleep loss, each scored from 0 to 10. The final SCORAD formula weights these components differently: A ÷ 5 + 7 × B ÷ 2 + C. Because the intensity signs are multiplied, clinically obvious inflammation can drive the score upward quickly, while severe itch and poor sleep also contribute meaningfully. Common interpretation bands are below 25 for mild disease, 25 to 50 for moderate disease, and above 50 for severe disease. Those cutoffs help clinicians communicate disease burden consistently, but the true impact on quality of life can vary. A smaller area of involvement on the face, hands, or genitals may be much more disruptive than a similar score located elsewhere. Likewise, a patient with only moderate visible inflammation may still have intense itch, repeated scratching, and major sleep disturbance. SCORAD is therefore most informative when it is read alongside patient history, trigger patterns, infection risk, and response to treatment. This calculator is valuable for standardizing assessment and tracking change over time. If a patient's SCORAD drops after topical therapy, phototherapy, systemic treatment, or trigger reduction, that provides an objective way to document improvement. Even so, it is still a support tool rather than a substitute for clinical judgment. Final treatment decisions should account for lesion distribution, age, complications, psychosocial impact, and the patient's own goals and symptom priorities.